세계의 매크로라이드계 항생제 시장 규모, 점유율, 성장 분석 : 약제별, 투여법별, 적응증별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)

Global Macrolide Antibiotics Market size was valued at USD 5.8 billion in 2023 and is poised to grow from USD 5.93 billion in 2024 to USD 7.12 billion by 2032, growing at a CAGR of 2.3% during the forecast period (2025-2032).

The macrolide antibiotic market is poised for growth, driven by a rising global prevalence of infectious diseases. Macrolides, characterized by their macrocyclic lactone structure and ability to inhibit protein synthesis by binding to the bacterial ribosome, are effective against various infections, including sexually transmitted diseases and respiratory ailments like pneumonia and bronchitis. The National Centre for Biotechnology Information reports significant rates of pneumonia, with incidences ranging from 1.5 to 14 cases per 1,000 people globally, and 24.8 cases per 10,000 in the United States, especially among older adults. The increasing demand for these antibiotics is further bolstered by the availability of generic options, as companies strive to develop equivalents to branded macrolides, enhancing their market presence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macrolide Antibiotics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macrolide Antibiotics Market Segmental Analysis

Global Macrolide Antibiotics Market is segmented by Drugs, Administration, Indication, End User and region. Based on Drugs, the market is segmented into Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin. Based on Administration, the market is segmented into Oral and Parenteral. Based on Indication, the market is segmented into Infection due to mycoplasma pneumonia, Legionella sp,or Bordetella pertussis, Symptomatic cat-scratch disease, Bacillary angiomatosis, Peliosis hepatis in patients with AIDS, Cebebral taxoplasmosis, Uncomplicated skin infection and Others. Based on End User, the market is segmented into Hospitals, Dermatology clinics, Pharmaceutical companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macrolide Antibiotics Market

The global macrolide antibiotics market is experiencing significant growth driven by emerging trends in developing nations such as China, India, and Brazil. These markets present substantial opportunities due to their large populations and increasing healthcare expenditures, which contribute to a rising demand for antibiotics. As bacterial infections become more prevalent in these regions, the need for effective treatment solutions continues to escalate. Consequently, manufacturers of macrolide antibiotics can expand their market presence and capitalize on the growing demand for innovative and efficient alternatives. This combination of factors positions the macrolide antibiotics market for remarkable expansion in the coming years.

Restraints in the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market faces significant constraints due to the increasing prevalence of antibiotic-resistant microorganisms, particularly to macrolides. This resistance primarily arises from the overuse and misuse of antibiotics, posing a critical challenge to the long-term viability of macrolide treatments for bacterial infections. As the effectiveness of these drugs diminishes, the market potential for macrolide antibiotics is compromised. Addressing the escalating issue of antibiotic resistance necessitates the development of new pharmacological options and alternative therapeutic strategies to ensure effective treatment and mitigate the impact of resistant bacteria on public health.

Market Trends of the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market is increasingly shaped by the urgent need to address bacterial resistance and enhance treatment efficacy. Pharmaceutical companies are innovating to develop new macrolide derivatives and advanced formulations, focusing on improving pharmacokinetics and expanding their spectrum of activity. This trend reflects a commitment to counteract evolving microbial threats while optimizing existing macrolide treatments for a wide range of bacterial infections. Additionally, increasing awareness of antibiotic resistance is driving research investments, suggesting a dynamic market landscape poised for growth. Consequently, the macrolide antibiotic sector is adapting to meet the pressing challenges posed by resistant pathogens in the healthcare environment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Macrolide Antibiotics Market Size by Drugs & CAGR (2025-2032)

• Market Overview
• Azithromycin
• Clarithromycin
• Erythromycin
• Fidaxomicin
• Telithromycin

Global Macrolide Antibiotics Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral

Global Macrolide Antibiotics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Infection due to mycoplasma pneumonia
• Legionella sp,or Bordetella pertussis
• Symptomatic cat-scratch disease
• Bacillary angiomatosis
• Peliosis hepatis in patients with AIDS
• Cebebral taxoplasmosis
• Uncomplicated skin infection
• Others

Global Macrolide Antibiotics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Dermatology clinics
• Pharmaceutical companies
• Others

Global Macrolide Antibiotics Market Size & CAGR (2025-2032)

• North America (Drugs, Administration, Indication, End User)
  • US
  • Canada
• Europe (Drugs, Administration, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drugs, Administration, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drugs, Administration, Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drugs, Administration, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zhejiang Guobang Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations